Nebula Research & Development LLC Has $538,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Nebula Research & Development LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 76.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,148 shares of the biopharmaceutical company’s stock after acquiring an additional 24,790 shares during the quarter. Nebula Research & Development LLC’s holdings in Amicus Therapeutics were worth $538,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Summit Investment Advisors Inc. raised its holdings in Amicus Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 1,280 shares during the last quarter. Xponance Inc. raised its stake in shares of Amicus Therapeutics by 11.9% during the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock valued at $200,000 after acquiring an additional 2,249 shares during the last quarter. Covestor Ltd raised its stake in shares of Amicus Therapeutics by 114.9% during the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 2,312 shares during the last quarter. KBC Group NV lifted its holdings in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 3,120 shares during the period. Finally, Swiss National Bank grew its stake in shares of Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company’s stock worth $4,121,000 after purchasing an additional 3,200 shares during the last quarter.

Analysts Set New Price Targets

FOLD has been the topic of several recent research reports. Wells Fargo & Company cut their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Trading Up 1.8 %

FOLD opened at $7.52 on Wednesday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a fifty day moving average price of $8.08 and a two-hundred day moving average price of $9.36. The company has a market cap of $2.31 billion, a P/E ratio of -41.78, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 1-year low of $6.20 and a 1-year high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.